These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 9671109

  • 1. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
    Gillberg PG, Sundquist S, Nilvebrant L.
    Eur J Pharmacol; 1998 May 22; 349(2-3):285-92. PubMed ID: 9671109
    [Abstract] [Full Text] [Related]

  • 2. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B.
    Eur J Pharmacol; 1997 May 30; 327(2-3):195-207. PubMed ID: 9200560
    [Abstract] [Full Text] [Related]

  • 3. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
    Nilvebrant L, Gillberg PG, Sparf B.
    Pharmacol Toxicol; 1997 Oct 30; 81(4):169-72. PubMed ID: 9353847
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K.
    Biol Pharm Bull; 2007 Jan 30; 30(1):54-8. PubMed ID: 17202659
    [Abstract] [Full Text] [Related]

  • 5. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.
    Nilvebrant L.
    Pharmacol Toxicol; 2002 May 30; 90(5):260-7. PubMed ID: 12076307
    [Abstract] [Full Text] [Related]

  • 6. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F, Yageta Y, Segawa M, Matsuzawa S.
    Arzneimittelforschung; 2007 May 30; 57(2):92-100. PubMed ID: 17396619
    [Abstract] [Full Text] [Related]

  • 7. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
    Kobayashi S, Ikeda K, Miyata K.
    Life Sci; 2004 Jan 02; 74(7):843-53. PubMed ID: 14659973
    [Abstract] [Full Text] [Related]

  • 8. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
    Nilvebrant L, Hallén B, Larsson G.
    Life Sci; 1997 Jan 02; 60(13-14):1129-36. PubMed ID: 9121357
    [Abstract] [Full Text] [Related]

  • 9. Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
    Wess J, Lambrecht G, Mutschler E, Brann MR, Dörje F.
    Br J Pharmacol; 1991 Jan 02; 102(1):246-50. PubMed ID: 2043926
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological effects of tolterodine on human isolated urinary bladder.
    Yono M, Yoshida M, Wada Y, Kikukawa H, Takahashi W, Inadome A, Seshita H, Ueda S.
    Eur J Pharmacol; 1999 Mar 05; 368(2-3):223-30. PubMed ID: 10193658
    [Abstract] [Full Text] [Related]

  • 11. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
    Nelson CP, Gupta P, Napier CM, Nahorski SR, Challiss RA.
    J Pharmacol Exp Ther; 2004 Sep 05; 310(3):1255-65. PubMed ID: 15140916
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
    Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S, Miyata K, Sasamata M.
    Eur J Pharmacol; 2004 May 25; 492(2-3):243-50. PubMed ID: 15178371
    [Abstract] [Full Text] [Related]

  • 13. Selectivity profile of some recent muscarinic antagonists in bovine and guinea-pig trachea and heart.
    Roffel AF, Hamstra JJ, Elzinga CR, Zaagsma J.
    Arch Int Pharmacodyn Ther; 1994 May 25; 328(1):82-98. PubMed ID: 7893193
    [Abstract] [Full Text] [Related]

  • 14. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug 25; 366(2):97-103. PubMed ID: 12122494
    [Abstract] [Full Text] [Related]

  • 15. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
    Moro C, Uchiyama J, Chess-Williams R.
    Urology; 2011 Dec 25; 78(6):1442.e9-15. PubMed ID: 22001099
    [Abstract] [Full Text] [Related]

  • 16. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S.
    J Urol; 2007 Feb 25; 177(2):766-70. PubMed ID: 17222678
    [Abstract] [Full Text] [Related]

  • 17. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D, Jarvis B.
    Drugs Aging; 2001 Feb 25; 18(4):277-304. PubMed ID: 11341475
    [Abstract] [Full Text] [Related]

  • 18. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
    Salcedo C, Davalillo S, Cabellos J, Lagunas C, Balsa D, Pérez-Del-Pulgar S, Ballarín M, Fernández A.
    Br J Pharmacol; 2009 Mar 25; 156(5):807-17. PubMed ID: 19222482
    [Abstract] [Full Text] [Related]

  • 19. UH-AH 37, an ileal-selective muscarinic antagonist that does not discriminate between M2 and M3 binding sites.
    Doods HN, Mayer N.
    Eur J Pharmacol; 1989 Feb 28; 161(2-3):215-8. PubMed ID: 2721554
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):145-52. PubMed ID: 19168050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.